Boston Scientific Announces Japanese Approval Of Heart Failure Lead

Boston Scientific
Corporation (NYSE: BSX) announced Japanese Ministry of Health, Labor
and Welfare (MHLW) approval of its ACUITY(R) Steerable left ventricular
lead for use with cardiac resynchronization therapy (CRT) devices, which
treat heart failure. The Company also received reimbursement approval for
the lead from the National Health Insurance System and plans to launch the
product immediately in Japan.

The ACUITY Steerable left ventricular lead features a deflectable tip
for successful delivery in simple, compound and complex anatomies, which
includes placement of the lead in difficult-to-access branch vessels on the
left side of the heart. A lead is an insulated wire that carries the heart
signal to the implanted device and delivers energy from the device to the
heart. In most cases, leads are passed into the heart through veins.

“We are pleased to make this lead available to physicians in Japan so
they can offer this advanced therapy to their heart failure patients,” said
Fred Colen, Executive Vice President, Operations and Technology, Boston
Scientific Cardiac Rhythm Management. “The ACUITY Steerable lead, when
teamed with our CRT devices, provides a proven, effective treatment option
to patients who struggle with heart failure.”

The ACUITY Steerable lead also provides physicians with four
configurations for stimulating the left side of the heart, which Boston
Scientific refers to as Electronic Repositioning(TM). This ability allows
physicians to change the stimulation site non-invasively after implant,
which helps avoid the need for an additional surgical procedure. Boston
Scientific is the only company that provides physicians with four left
ventricular pacing configurations.

Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like “anticipate,”
“expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar
words. These forward- looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and
are not intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our product performance, regulatory approval of our products, new
product launches, competitive offerings, our growth strategy, and our
market position. If our underlying assumptions turn out to be incorrect, or
if certain risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or implied by
our forward-looking statements. These factors, in some cases, have affected
and in the future (together with other factors) could affect our ability to
implement our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business decisions
made by us and our competitors. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A-
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A
– Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward- looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

Boston Scientific Corporation

This entry was posted in Uncategorized. Bookmark the permalink.